Is it safe to use trazodone when planning pregnancy, and does it affect fertility or the effectiveness of contraceptive methods?

Trazodone and Family Planning

Trazodone can be continued during pregnancy planning and pregnancy when needed for maternal mental health, as available evidence shows no consistent increased risk of major congenital malformations, though some data suggest possible associations with spontaneous abortion that require careful counseling.

Safety Profile During Pregnancy

The FDA drug label for trazodone indicates that published prospective cohort studies, case series, and case reports over several decades have not identified drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes 1. A 2025 systematic review of 14 studies found no consistent evidence linking trazodone use during pregnancy to increased risks of congenital malformations, stillbirths, or low birth weight 2.

Key evidence from controlled studies:

• A multicentre prospective study of 147 pregnant women exposed to trazodone found a major malformation rate of 1.6%, which did not differ significantly from control groups taking other antidepressants or nonteratogenic drugs 3
• This rate falls within the baseline population risk of 1-3% for major malformations
• No statistically significant differences were found in spontaneous abortion rates, gestational age, or birth weight compared to controls

Important Caveats and Concerns

Potential risks requiring discussion:

• Some studies suggest a possible association with increased spontaneous and therapeutic abortions, though confounding by indication (untreated depression itself) cannot be ruled out 2
• Animal studies showed increased fetal resorption at doses 7.3-11 times the maximum recommended human dose, and congenital anomalies in rabbits at 7.3-22 times human doses 1
• A 2021 preclinical study raised concerns about trazodone interfering with sterol biosynthesis during brain development, particularly in fetuses with DHCR7 heterozygous genotype 4, though clinical significance in humans remains unclear

Effect on Fertility

Male fertility concerns:

• Recent animal research (2026) demonstrated that trazodone caused testicular tissue damage, reduced sperm production and count, decreased progressive motility, and impaired epididymal duct contractility in rats 5
• These findings suggest potential male fertility impairment, though human data are lacking
• Men planning conception should discuss these potential risks with their healthcare provider

Female fertility:

• No direct evidence suggests trazodone impairs female fertility
• Trazodone does not affect the effectiveness of contraceptive methods 6, 7

Clinical Decision-Making Algorithm

For women planning pregnancy:

1. Assess disease severity: Evaluate the risk of untreated depression/insomnia versus medication exposure. Women who discontinue antidepressants during pregnancy are more likely to experience relapse 1

2. Preconception counseling: Engage in detailed risk-benefit discussion covering:

   • No established teratogenic risk in humans
   • Possible increased spontaneous abortion risk (unclear if drug-related or disease-related)
   • Risks of untreated maternal mental illness on pregnancy outcomes

3. If continuing trazodone:

   • Use the lowest effective dose
   • Ensure adequate folic acid supplementation (standard prenatal dose)
   • Monitor maternal mental health closely throughout pregnancy
   • Register with the National Pregnancy Registry for Antidepressants (1-844-405-6185) 1

4. If discontinuing: Taper gradually to avoid discontinuation syndrome; ensure alternative management strategies for depression/insomnia are in place

For male partners planning conception:

• Consider the emerging animal data on male fertility effects
• If fertility issues arise, discuss potential medication alternatives with healthcare provider
• Note that human data on male fertility effects are currently absent

Breastfeeding Considerations

The FDA label states that trazodone transfers into human milk, but limited postmarketing reports have not identified adverse effects on breastfed children 1. The developmental and health benefits of breastfeeding should be weighed against the mother's clinical need for trazodone 1.

Common Pitfalls to Avoid

• Do not automatically discontinue trazodone upon pregnancy confirmation without assessing the risk of untreated maternal illness, which can itself harm pregnancy outcomes
• Do not assume all antidepressants carry equal pregnancy risks—trazodone's safety profile differs from known teratogens like paroxetine
• Do not overlook the quality of available evidence—most trazodone pregnancy data come from observational studies with methodological limitations including small sample sizes 2
• Do not ignore emerging male fertility data when counseling couples, even though human evidence is lacking

The balance strongly favors continuing trazodone when maternal mental health requires it, as untreated depression poses documented risks to both mother and fetus, while trazodone's fetal risks remain theoretical or minimal based on decades of human use.